{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:08:32Z","timestamp":1780628912911,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,2,9]],"date-time":"2006-02-09T00:00:00Z","timestamp":1139443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To investigate the clinical application of octreotide\u2010LAR as primary treatment in newly diagnosed patients with GH\u2010secreting pituitary tumours.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design\u2002<\/jats:bold>\n                    Open, prospective, multicentre, 24\u2010week follow\u2010up study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients\u2002<\/jats:bold>\n                    Thirty\u2010four patients were enrolled (20 men, 14 women; mean age, 50\u00a0years); 13 had microadenoma [median tumour volume 327\u00a0mm\n                    <jats:sup>3<\/jats:sup>\n                    (range 31\u2013629\u00a0mm\n                    <jats:sup>3<\/jats:sup>\n                    )], 21 had macroadenoma [median tumour volume 1325\u00a0mm\n                    <jats:sup>3<\/jats:sup>\n                    (range 503\u201311583\u00a0mm\n                    <jats:sup>3<\/jats:sup>\n                    )].\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Interventions\u2002<\/jats:bold>\n                    Octreotide\u2010LAR at the dosage of 20\u00a0mg every 28\u00a0days for the first 12\u00a0weeks increased to 30\u00a0mg every 28\u00a0days to control GH and\/or IGF\u2010I excess in 20 patients (64\u00b77%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main outcome measures\u2002<\/jats:bold>\n                    Primary endpoints were control of GH (fasting &lt; 2\u00b75 \u00b5g\/l) and IGF\u2010I secretion (gender\u2010 and age\u2010normalized) and presence and entity of tumour mass shrinkage. Secondary endpoint was improvement of symptoms score.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    In patients with micro\u2010 and macroadenomas GH levels decreased to &lt; 2\u00b75\u00a0\u00b5g\/l in 84\u00b76% and 45%, serum IGF\u2010I levels normalized for age and gender in 61\u00b75% and 35% of cases. Failure in achieving either GH\u00a0&lt;\u00a02\u00b75\u00a0\u00b5g\/l or normal IGF\u2010I levels was found in none of the patients with micro\u2010 and in 45% of patients with macroadenoma. Median tumour volume was reduced by 54% (range: \u221290% to +350%) in micro\u2010 and by 49% (range \u221294% to \u221214%) in macroadenomas. Headache, perspiration and osteo\u2010arthralgias disappeared in 21%, paresthesias in 38%, fatigue in 26% and carpal tunnel syndrome in 15%. The treatment was well tolerated: more frequent adverse events were gastrointestinal (in 44%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2002<\/jats:bold>\n                    In both patients with micro\u2010 or macroadenoma, primary octreotide\u2010LAR treatment controls hormone excess, induces tumour shrinkage and improves symptoms of acromegaly with limited side effects and can be therefore successfully employed in patients with contraindications for surgery or in those who refuse surgery.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2265.2006.02467.x","type":"journal-article","created":{"date-parts":[[2006,2,9]],"date-time":"2006-02-09T11:14:33Z","timestamp":1139483673000},"page":"342-351","source":"Crossref","is-referenced-by-count":63,"title":["First\u2010line octreotide\u2010LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial"],"prefix":"10.1111","volume":"64","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Tita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"De Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Barreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Mainini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,2,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03356-X"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03135.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb00805.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0954-6820.1988.tb15881.x","article-title":"Epidemiology and long\u2010term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984","volume":"223","author":"Bengtsson B.A.","year":"1988","journal-title":"Acta Medica Scandinavica"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb03789.x"},{"key":"e_1_2_6_7_2","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study","volume":"83","author":"Orme S.M.","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-6374(03)00030-3"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.10.3419"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01679.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-011841"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01734.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0022"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-5-1040"},{"key":"e_1_2_6_15_2","first-page":"765","article-title":"Long\u2010term octreotide therapy in growth hormone\u2010secreting pituitary adenomas: evaluation with serial MR","volume":"18","author":"Lundin P.","year":"1997","journal-title":"American Journal of Neuroradiology"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jcem.82.10.4283","article-title":"Effect of octreotide pretreatment on surgical outcome in acromegaly","volume":"82","author":"Colao A.","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.6.2779"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2001-012012"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1330430"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.2.526"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-51-4-781"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00009"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-2-391"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/archinte.1991.00400080073013","article-title":"Long\u2010term treatment of 189 acromegalic patients with the somatostatin analogue octreotide. Results of the International Multicenter Acromegalic Study Group","volume":"151","author":"Vance M.L.","year":"1991","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.9.3034"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2466"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1093"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.11.4099"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0300-0664.2001.01438.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01741.x"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2006.02467.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2006.02467.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:12:12Z","timestamp":1697213532000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2006.02467.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1365-2265.2006.02467.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02467.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.14596.472107","asserted-by":"object"}]},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,9]]}}}